NewGen BioPharma Corp. (NEWG)

[Big Brother]

The cannabis products they are developing certainly have a lot of potential but their nano-cyclosporine product, NanoTears, currently on sale in India, could end up being their flagship product. Especially if it is proven to be more effective than Restasis, Restasis generates well over $1 Billion dollars in sales per year.

Sunways (India), Private Ltd – Our lead formulation, Nano-cyclosporine for dry eye, “NanoTearsTM”, was launched by our marketing partner, Sunways in India in April, 2015. Sunways, incorporated in 1951 and based in Mumbai, is a medium sized pharma company that manufactures and markets a wide range of formulations in ophthalmology and ENT.

http://www.sunways.com/JV.html

http://www.sunways.com/Products/SunwaysProducts/Nano-Tears-0-005.html

MNP-Cyclosporine for dry eye – approved and already marketed in India. Filing for approval in other emerging markets. Currently initiating head to head proof-of-concept Phase II study versus Restasis. MNP Cyclosporine has demonstrated fasted drug release and 4x more binding versus standard of care Restasis of Allergan. If these pre-clinical differences lead to superior clinical benefits versus Restasis such as, an earlier onset of action and less corneal irritation, then we expect MNP-Cyclosporine to have a multi-hundred million dollars in peak sales potential and to drive significant value for NewGen in the next two years.